CVS, Humana, Elevance Hint at ’25 Benefit Reductions on 1Q Earnings Calls

As Medicare Advantage insurers contemplate 2025 bids in an unfavorable funding environment, select firms that reported first-quarter 2024 earnings at press time indicated their preference for margin recovery versus growth and the likelihood of service area/benefit reductions next year.

For the quarter ending March 31, 2024, CVS Health Corp. on May 1 reported consolidated revenues of $88.4 billion, reflecting year-over-year revenue growth of 3.7% that would have been larger if not for a decline in the Health Services segment. Meanwhile, first quarter adjusted earnings per share (EPS) dropped from $2.20 a year ago to $1.31, which the company attributed to utilization pressure in the Health Care Benefits segment’s MA business. That segment’s medical loss ratio (MLR) was 90.4%, compared with 84.6% in the prior-year quarter, while higher-than-expected medical costs of approximately $900 million — primarily driven by MA — were due to seasonal factors or items specific to the quarter, the company clarified.

© 2024 MMIT
Lauren Flynn Kelly

Lauren Flynn Kelly Managing Editor, Radar on Medicare Advantage

Lauren has been covering health business issues since the early 2000s and specializes in in-depth reporting on Medicare Advantage, managed Medicaid and Medicare Part D. She also possesses a deep understanding of the complex world of pharmacy benefit management, having written AIS Health’s Radar on Drug Benefits from 2004 to 2005 and again from 2011 to 2016. In addition to her role as managing editor of Radar on Medicare Advantage, she oversees AIS Health’s publications and manages the health editorial staff. She graduated from Vassar College with a B.A. in English.

Related Posts

senior-fitness-class
April 18

With Less Funding, MAOs Seek Creative Tradeoffs to Preserve Benefits

READ MORE
reimbursement
April 4

No News Is Bad News for MAOs Hoping to See Pay Hike in 2025

READ MORE
stethoscope-clipboard
February 15

MA Industry Braces for Part C Rate Cut, Part D Benefit Shakeup

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today